CURED Trial: Cognitive Bias Modification for Depression

SNIPPET: CURED (Cognitive bias modification Utilised to Rectify Errors for Depression) is a new six-session, pen-and-paper CBM-I intervention co-designed with people who have lived experience of depression. A double-blind feasibility RCT with 60 adults is now underway to test its safety, acceptability, and feasibility before a full efficacy trial. Early evidence from adjacent CBM studies suggests attentional and interpretation bias training may reduce depressive mood, but CURED's specific outcomes are not yet known.

THE PROTOHUMAN PERSPECTIVE#

Depression doesn't just feel bad. It reshapes how the brain filters reality — what gets noticed, what gets remembered, what meaning gets assigned to an ambiguous glance from a colleague. That's not a metaphor. It's a measurable cognitive architecture, and it's been quietly driving relapse rates of 50–80% in Major Depressive Disorder for decades^[2].

What makes CURED interesting isn't the mechanism itself — cognitive bias modification has been around since the early 2000s. It's the delivery model. Six paper booklets, mailed to your home, with remote researcher support. No app subscription. No therapist waitlist. No clinic. If the feasibility data holds, this could become one of the most accessible mental health interventions ever tested in a rigorous trial format. For anyone tracking the intersection of cognitive optimization and scalable health, this is the kind of low-cost, high-reach protocol that actually changes population-level outcomes — not just individual biohacker stacks.

THE SCIENCE#

What Cognitive Bias Modification Actually Does#

I think the word "bias" is doing too much work here, so let me be precise. In depression, interpretation bias means ambiguous information gets funnelled through a negative filter automatically — before conscious reasoning kicks in. You hear "we need to talk" and your nervous system has already decided it's catastrophic. CBM-I (Cognitive Bias Modification for Interpretation) trains a different default. Through repeated exposure to ambiguous scenarios that resolve positively, the brain begins recalibrating its automatic interpretive machinery^[6].

This isn't positive thinking. It operates below the level of deliberate cognition, closer to where attentional allocation and pattern-completion happen. Think of it as retraining the predictive coding layer — the part of the brain that fills in gaps before you've finished reading the sentence.

The CURED Protocol Specifically#

CURED was developed to address a specific problem: previous CBM-I interventions showed weaker effects in depression compared to anxiety^[1]. The developers took a different approach — co-designing the intervention with people who have actually lived through depressive episodes, then refining it with clinician input. That collaborative development process is unusual for this type of intervention and may help explain why earlier CBM-I efforts felt disconnected from the actual phenomenology of depression.

The trial itself is a double-blind, parallel-group feasibility RCT with 60 adults meeting clinical depression criteria. Participants are randomised 1:1 to either six weekly CURED sessions or a neutral CBM-I control that matches format, length, and delivery but differs in content^[1]. Both arms receive pen-and-paper booklets by mail. Assessment occurs at baseline, 6 weeks (post-treatment), and 12-week follow-up.

Primary outcomes are feasibility metrics: recruitment rates, retention, adherence, blinding integrity, and safety. Secondary outcomes include interpretation bias, depressive and anxiety symptoms, cognitive content and processes, and psychosocial functioning^[1].

Let me be direct about what this means: we do not yet have efficacy data from CURED. This is a feasibility protocol. The question being asked isn't "does it work?" but "can we run a proper trial to find out if it works?" That distinction matters.

Adjacent Evidence: What ABM and Related CBM Trials Show#

But here's where it gets complicated. While CURED itself has no outcomes yet, adjacent trials give us a useful — if messy — picture.

A 2025 RCT published in Scientific Reports tested attentional bias modification (ABM) on depressive affect in 45 participants aged 18–40. The experimental group showed statistically significant reductions in both attentional bias and depressive mood (F(2, 42) = 6.73, p < 0.05, η² = 0.24), with faster reaction times to positive stimuli compared to placebo (F(2, 42) = 5.18, p = 0.01, η² = 0.20)^[4]. That η² of 0.24 is a large effect size. But — and I'd want to see this replicated before changing my protocol — the sample was 45 people. Fifteen per group. That's not nothing, but it's not definitive either.

The SMARD trial protocol, also from 2025, takes a different angle entirely. It compares smartphone-delivered Memory Bias Modification Training, Cognitive Control Training, and Attention Bias Modification Training in 120 remitted MDD patients, with a 1.5-year follow-up tracking recurrence^[2]. What's notable here is the use of BEHAPP, a passive mobile monitoring app that tracks behavioural changes indicative of an imminent depressive episode. The integration of passive monitoring with cognitive training represents what the authors call a "second-generation recurrence prevention program."

A pilot crossover study by Legenbauer et al. (2025) in Frontiers in Psychology tested a visual CBM paradigm — a two-alternative forced choice task — in adolescent inpatients with anorexia (n=12) or depression (n=17). The CBM shifted perceptual boundaries significantly, and t-test comparisons revealed improved depression-specific symptoms in the depression group^[3]. The catch, though: the control condition wasn't neutral. It shifted perceptual boundaries toward lower BMI in anorexia patients, which is exactly the opposite of what you'd want. That's a design problem that needs solving.

Wang et al. (2025) in Cognitive Therapy and Research looked at who actually benefits from single-session CBM-I. In high worriers with anxiety/depression histories (N=83), greater positive imagery ability and lower cognitive flexibility predicted larger gains in positive interpretation bias^[5]. The non-replication across their two samples is honestly more interesting than the positive findings — it suggests that CBM-I responsiveness is highly individual, and blanket protocols may not be the answer.

COMPARISON TABLE#

THE PROTOCOL#

How to engage with cognitive bias modification principles based on current evidence. Important caveat: CURED is not publicly available yet. These steps draw from the broader CBM literature and the protocols described in the research.

Step 1: Assess your baseline interpretation style. Pay attention to how you automatically interpret ambiguous situations over one week. Keep a brief log — three entries per day — noting the event, your first interpretation, and whether it was negative, neutral, or positive. This isn't journaling therapy; it's data collection. You're establishing a baseline.

Step 2: Practise ambiguity resolution exercises. Using CBM-I principles, write or source 10 ambiguous social scenarios per session (e.g., "Your friend doesn't reply to your message for hours"). For each, generate the negative interpretation your mind defaults to, then deliberately construct and sit with a benign or positive resolution. Do this daily for 15–20 minutes.

Step 3: Train attentional reallocation. Based on ABM evidence^[4], practise shifting attention toward positive or neutral stimuli. A simple version: set a timer for 5 minutes and, while scrolling through any media feed, deliberately pause on neutral or positive content for 3 seconds before moving on. Skip negative content without engaging. Do this once daily.

Step 4: Use positive mental imagery deliberately. Wang et al.'s data suggests that the ability to vividly imagine positive events predicts better CBM-I outcomes^[5]. Spend 5 minutes daily generating detailed sensory-rich mental images of positive scenarios — not vague optimism, but specific scenes with sounds, textures, and spatial detail.

Step 5: Track changes weekly. Use a standardised self-report measure (the PHQ-9 is freely available) to track depressive symptoms at the same time each week. Plot your scores. You're looking for trends, not single data points.

Step 6: Consider professional integration. If you're experiencing clinical depression, these techniques supplement — they do not replace — evidence-based treatment. The honest answer is that CBM alone has not been shown to match CBT or pharmacotherapy for moderate-to-severe depression. Discuss adding CBM-based exercises with your clinician.

What is Cognitive Bias Modification for Interpretation (CBM-I)?#

CBM-I is a training technique that targets the automatic tendency to interpret ambiguous information negatively — a pattern strongly associated with depression and anxiety. It works by repeatedly exposing individuals to ambiguous scenarios that resolve positively, gradually retraining the brain's default interpretive response. Unlike traditional CBT, it operates below conscious deliberation, targeting automatic rather than reflective cognition.

How is CURED different from previous CBM interventions?#

CURED was co-developed with people who have lived experience of depression, which is unusual for this type of intervention. Previous CBM-I protocols were largely designed by researchers and showed weaker effects in depression compared to anxiety. CURED also uses a pen-and-paper format delivered by mail — removing the need for digital devices, internet access, or clinical appointments — which makes it potentially more accessible than app-based alternatives.

Who might benefit most from cognitive bias modification?#

Based on Wang et al.'s 2025 research, individuals with strong positive mental imagery ability may respond better to single-session CBM-I^[5]. The relationship with cognitive flexibility was inconsistent across samples, which suggests we don't yet have a reliable predictor profile. Honestly, we don't know yet who the ideal candidate is — that's partly what trials like CURED and SMARD are designed to figure out.

When will efficacy data from the CURED trial be available?#

The CURED protocol was published in April 2026, and the trial is currently recruiting 60 participants with 12-week follow-up^[1]. Assuming recruitment and data collection proceed on schedule, preliminary efficacy signals may emerge within the next 12–18 months, with a full definitive trial to follow if feasibility is confirmed.

Why does depression have a 50–80% recurrence rate despite existing treatments?#

Current treatments like CBT and SSRIs are effective for acute episodes but may not sufficiently target the underlying cognitive mechanisms — particularly automatic biases in memory, attention, and interpretation — that persist into remission and drive relapse^[2]. These biases operate outside conscious awareness, which means they can quietly rebuild the cognitive architecture of depression even when someone feels recovered.

VERDICT#

Score: 6/10

I'm scoring CURED and the broader CBM-for-depression landscape cautiously. The CURED design is smart — lived-experience co-development, low-cost delivery, rigorous blinding — but it's a feasibility protocol. No efficacy data exists yet. The adjacent evidence is genuinely encouraging: ABM shows large effect sizes in small samples, and the SMARD protocol could yield meaningful recurrence prevention data. But the field is littered with non-replications and small samples. I'm less convinced by the body image CBM pilot, where the control condition behaved non-neutrally — that kind of methodological issue makes me want clearer data before getting excited. If CURED's feasibility holds and the definitive RCT delivers, this could shift to an 8. For now, it's promising infrastructure, not proven intervention.